Video

Use of aflibercept in the management of diabetic retinopathy

Author(s):

David Hutton,Emily Kaiser Maharjan
Conferences|ASRS Preview

Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.

Lloyd Clark, MD, of Palmetto Retina Center, previews his ASRS poster, which focuses on the PANORAMA Study, which reviews the use of aflibercept in the management of diabetic retinopathy. He will present his poster during a reception on July 15 at this year’s American Society of Retina Specialists meeting in New York.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)
June 27th 2025

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
June 26th 2025

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001
June 25th 2025

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001

(Image credit: AdobeStock/WS Studio 1985)
June 25th 2025

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

© 2025 MJH Life Sciences

All rights reserved.